Navigation Links
ARIUS announces first quarter fiscal 2008 financial results
Date:4/11/2008

eparing for a pre-IND meeting with the FDA planned for the third

quarter of 2008, and the filing of a Phase I IND application

anticipated in late 2008.

CD59 Complement Inhibitor Program

- Selected to present a CD59-focused poster at AACR Annual Meeting.

- Generated a cell line producing humanized CD59 antibody that

successfully retained binding characteristics and potent in vivo

activity.

- Preparing to perform preclinical toxicology studies planned for

2008 in preparation for filing a Phase I IND application.

CD9 Cancer Stem Cell Program

- Selected to present a CD9-focused poster at AACR Annual Meeting.

- Presented positive findings demonstrating the ability of the lead

anti-CD9 antibody to kill cancer stem cells in an in vivo model

using cells from human leukemia patients at the American

Association of Cancer Research Special Conference on Cancer Stem

Cells.

CD63 Antibody Program

- Licensed to Genentech, Inc. in March 2006, the CD63 program

continues to advance in preclinical studies in a variety of cancer

indications as part of a program to move the lead antibody towards

the clinic.

Takeda Collaboration

- Discovered and delivered novel antibodies to Takeda. Under the

terms of the research collaboration agreement, ARIUS has

successfully met its obligations to date and has received all

scheduled research payments from Takeda.

Additional Product Updates

- Currently, ARIUS has antibody programs targeting the MCSP antigen

and 37LRP, in addition to several other undisclosed programs.

- ARIUS currently has 23 issued or allowed patents covering its

antibody programs and discovery platform and over 228 patents


'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... African-Americans in STEM industries, Black Data Processing Associates (BDPA), ... Day on June 8, 2013. This all-day event will ... arena, and learn the ins and outs from many ... to 3 p.m. at the New Jersey Institute of ...
(Date:5/23/2013)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... a teleconference to discuss its First Quarter 2013 financial ... information is provided below: Date: Thursday, May ... Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ( ... For those unable to participate in the ...
(Date:5/23/2013)... May 23, 2013  Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, today announced ... Officer, will present at two upcoming conferences. ... present at the Second Annual Marcum LLP Microcap Conference ... Hotel in New York City.  The presentation is scheduled ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... Inc. announced today that it has initiated patient enrollment ... lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes ... regeneration of cartilage in patients suffering from severe osteoarthritis ... placebo-controlled Phase II study will evaluate the safety and ...
... animals grew far more complex than their single-celled ancestors. ... finds that complex organisms, including humans, have accumulated structural ... from microbe to man. The study, published in ... errors into proteins, rather than traditional natural selection, may ...
... 2011 Cellectis bioresearch, a subsidiary of Cellectis ... Wako Pure Chemical Industries as its distributor in ... products and services, including the recently launched TALEN(1) ... distributor of research products in Japan. ...
Cached Biology Technology:TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee 2Errors in protein structure sparked evolution of biological complexity 2Errors in protein structure sparked evolution of biological complexity 3Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan 2
(Date:5/22/2013)... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ... finely-tuned microwave fields to identify molecular variants apart, and ...
(Date:5/22/2013)... environmental and human health effects from disposal of ... led scientists to recommend stronger government policies to ... battery materials. That,s the conclusion of a new ... & Technology . , Oladele A. Ogunseitan and ... mainstays for powering everything from smart phones to ...
(Date:5/22/2013)... Early screening for prostate cancer could become as ... women, thanks to UC Irvine research published today in ... , After more than a decade of work, UC ... clinically usable markers for prostate cancer in urine, meaning ... greater accuracy and at dramatically lower cost. The same ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... the landscape industry revealed the importance of arming ... application, and problem-solving skills. Teaching students the skills ... crucial to their career success. With the ... decades, tools are now available to present students ...
... SAN FRANCISCO, Dec. 29, 2008 -- Facial expressions of ... study published today in the Journal of Personality ... expressions of emotion are innate rather than a product ... its kind to demonstrate that sighted and blind individuals ...
... Dec. 9 First Coast Service Options (FCSO) ... in Medicare reimbursement solutions, to support a new ... Medicare & Medicaid Services (CMS).Under this new contract, ... 2009 between health care providers and organizations offering ...
Cached Biology News:Web-based case studies help students develop career skills 2Facial expressions of emotion are innate, not learned, says new study 2FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract 2